Literature DB >> 14715784

Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.

M A Pfaller1, S A Messer, L Boyken, C Rice, S Tendolkar, R J Hollis, D J Diekema.   

Abstract

We evaluated the NCCLS M44-P fluconazole disk diffusion method in comparison with the NCCLS M27-A2 broth microdilution method for determining the susceptibility of 276 isolates of Cryptococcus neoformans. Disk diffusion testing was performed using Mueller-Hinton agar supplemented with 2% glucose and 0.5 microg of methylene blue/ml. Among the 276 isolates, 259 (93.8%) were susceptible, 16 (5.8%) were susceptible--dose dependent, and 1 (0.4%) was resistant to fluconazole as determined by the NCCLS broth microdilution method. The overall categorical agreement between the two methods was 86%, with 0% very major errors, 2% major errors, and 12% minor errors. The disk diffusion method using Mueller-Hinton agar supplemented with glucose and methylene blue appears to be a useful approach for determining the fluconazole susceptibility of C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715784      PMCID: PMC321716          DOI: 10.1128/JCM.42.1.380-383.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

Authors:  Sara A Mirza; Maureen Phelan; David Rimland; Edward Graviss; Richard Hamill; Mary E Brandt; Tracie Gardner; Matthew Sattah; Gabriel Ponce de Leon; Wendy Baughman; Rana A Hajjeh
Journal:  Clin Infect Dis       Date:  2003-02-27       Impact factor: 9.079

2.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

3.  In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors:  M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

5.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

6.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Authors:  P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

7.  Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.

Authors:  C J Jessup; M A Pfaller; S A Messer; J Zhang; M Tumberland; E K Mbidde; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

8.  In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).

Authors:  S T Yildiran; A W Fothergill; D A Sutton; M G Rinaldi
Journal:  Mycoses       Date:  2002-11       Impact factor: 4.377

9.  Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.

Authors:  A L Barry; M A Pfaller; R P Rennie; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 10.  Cryptococcosis.

Authors:  John R Perfect; Arturo Casadevall
Journal:  Infect Dis Clin North Am       Date:  2002-12       Impact factor: 5.982

View more
  6 in total

1.  Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.

Authors:  A Espinel-Ingroff; E Canton; D Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

Review 2.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

3.  Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth.

Authors:  Steven S Giles; Ines Batinic-Haberle; John R Perfect; Gary M Cox
Journal:  Eukaryot Cell       Date:  2005-01

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

5.  Metal Complexes of a Novel Schiff Base Based on Penicillin: Characterization, Molecular Modeling, and Antibacterial Activity Study.

Authors:  Narendra Kumar Chaudhary; Parashuram Mishra
Journal:  Bioinorg Chem Appl       Date:  2017-06-08       Impact factor: 7.778

6.  Antifungal activity of eugenol on Cryptococcus neoformans biological activity and Cxt1p gene expression.

Authors:  Parviz Hassanpour; Masoomeh Shams-Ghahfarokhi; Mehdi Razzaghi-Abyaneh
Journal:  Curr Med Mycol       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.